Download PDF
Semin Thromb Hemost 2001; 27(4): 405-416
DOI: 10.1055/s-2001-16893
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Recombinant Antithrombin: Production and Role in Cardiovascular Disorder

Jerrold H. Levy1 , Andrew Weisinger1 , Carol A Ziomek2 , Yann Echelard Ph.D.2
  • 1Departments of Anesthesiology, Emory University School of Medicine, and Division of Cardiothoracic Anesthesiology and Critical Care, Emory Healthcare, Atlanta, Georgia
  • 2Genzyme Transgenics Corporation, Framingham, Massachusetts
Further Information

Publication History

Publication Date:
31 August 2001 (online)

    Permissions and Reprints

ABSTRACT

Plasma-derived antithrombin (AT) concentrates have been used for the management of hereditary and acquired deficiencies since the early 1980s. Recombinant versions of other blood factors and their derivatives are increasingly becoming available, providing a safe and abundant supply of these important therapeutics. However, the complexity of the AT molecule and the large doses often required for supplementation treatments preclude the use of traditional cell culture bioreactors for recombinant production. The development of a very efficient expression system has been necessary for the cost-efficient recombinant production of AT. Transgenic production, with its ability to yield high levels of heterologous protein and its scale-up flexibility, is an attractive alternative to plasma fractionation. Purification of recombinant AT from the milk of transgenic dairy goats has been developed to provide a homogeneous, well-defined, and abundant supply of this factor. This article describes the production of recombinant AT and aspects of clinical applications of this molecule to cardiovascular disorders.

KEYWORD

Recombinant antithrombin - transgenic production - cardiopulmonary bypass - heparin resistance - clinical trials

REFERENCES

  • 1 Abildgaard U. Binding of thrombin to antithrombin III.  Scand J Clin Lab Invest . 1969;  24 23-27
    PubMedGoogle Scholar
  • 2 Yin E T, Wessler S, Stoll P J. Identity of plasma-activated factor X inhibitor with antithrombin 3 and heparin cofactor.  J Biol Chem . 1971;  246 3712-4719
    PubMedGoogle Scholar
  • 3 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor.  J Biol Chem . 1973;  248 6490-6505
    PubMedGoogle Scholar
  • 4 Rosenberg J S, McKenna P, Rosenberg R D. Inhibition of human factor IXa by human antithrombin-heparin cofactor.  J Biol Chem . 1975;  248 8883-8889
    PubMedGoogle Scholar
  • 5 Kurachi K, Fujikawa, Schmer G, Davie E W. Inhibition of bovine factor IXa and factor Xa by antithrombin III.  Biochemistry . 1976;  15 373-377
    CrossrefPubMedGoogle Scholar
  • 6 Stead N, Kaplan A P, Rosenberg R D. Inhibition of activated factor XII by antithrombin-heparin cofactor.  J Biol Chem . 1976;  251 6481-6488
    PubMedGoogle Scholar
  • 7 Kondo S, Kisiel W. Regulation of factor VIIa activity in plasma: evidence that antithrombin III is the sole plasma protease inhibitor of human factor VIIa.  Thromb Res . 1987;  46 325-335
    CrossrefPubMedGoogle Scholar
  • 8 Blajchman M A, Austin R, Fernandez-Rachubinski F, Sheffield W P. Molecular basis of an inherited human antithrombin deficiency.  Blood . 1992;  80 2159-2171
    PubMedGoogle Scholar
  • 9 Andersson L-O, Engman L, Henningson E. Crossed immunoelectrophoresis applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin-thrombin complex.  J Immunol Methods . 1977;  14 271-281
    CrossrefPubMedGoogle Scholar
  • 10 Perlmutter D H, Glover G I, Rivertna M. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes.  Proc Natl Acad Sci USA . 1990;  87 3753-3757
    PubMedGoogle Scholar
  • 11 Pizzo S V. Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes.  Am J Med . 1989;  87(Suppl 3B) 10S-14S
    PubMedGoogle Scholar
  • 12 Egeberg O. Inherited antithrombin deficiency causing thrombophilia.  Thromb Diath Haemorrh . 1965;  13 516-530
    PubMedGoogle Scholar
  • 13 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism.  Clin Haematol . 1981;  10 369-390
    PubMedGoogle Scholar
  • 14 Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency.  Am J Med . 1989;  87(Suppl 3B) 34S-8S
    PubMedGoogle Scholar
  • 15 Lechner K, Kyrle P A. Antithrombin III concentrates-are they clinically useful?.  Thromb Haemost . 1995;  73 340-348
    PubMedGoogle Scholar
  • 16 van Boven H H, Lane D A. Antithrombin and its inherited states.  Semin Hematol . 1997;  34 188-204
    PubMedGoogle Scholar
  • 17 Büller H R, ten Cate W J. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate.  Am J Med . 1989;  87(3B) 44S-48S
    PubMedGoogle Scholar
  • 18 Mammen E F. Clinical relevance of antithrombin deficiencies.  Semin Thromb Haemost . 1995;  32 2-6
    PubMedGoogle Scholar
  • 19 Baker Jr F W, Bick R L. Treatment of hereditary and acquired thrombophilic disorders.  Semin Thromb Hemost . 1999;  25 387-406
    PubMedGoogle Scholar
  • 20 Smith-Erichsen N, Aasen A O, Gallimore M J, Amundsen E. Studies of components of the coagulation systems in normal individuals and septic shock patients.  Circ Shock . 1982;  9 491-497
    PubMedGoogle Scholar
  • 21 Wilson R F, Farag A, Mammen E F, Fujii Y. Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients.  Am Surg . 1989;  55 450-456
    PubMedGoogle Scholar
  • 22 Fourrier F, Chopin C, Goudemand J. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.  Chest . 1992;  101 816-823
    CrossrefPubMedGoogle Scholar
  • 23 Wilson R F, Mammen E F, Tyburski J G, Warsow K M, Kubinec S M. Antithrombin levels related to infections and outcome.  J Trauma . 1996;  40 384-387
    PubMedGoogle Scholar
  • 24 Owings J T, Bagley M, Gosselin R, Romac D, Disbrow E. Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications.  J Trauma . 1996;  41 396-405
    CrossrefPubMedGoogle Scholar
  • 25 Blauhut B, Necek S, Vinazzer H, Bergmann H. Substitution therapy with an antithrombin III concentrate in shock and DIC.  Thromb Res . 1982;  27 271-278
    CrossrefPubMedGoogle Scholar
  • 26 Vinazzer H. Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation.  Semin Thromb Hemost . 1989;  15 347-352
    PubMedGoogle Scholar
  • 27 Menache D, O'Malley J P, Schorr J B. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency.  Cooperative Study Group. Blood . 1990;  75 33-39
    PubMedGoogle Scholar
  • 28 Fourrier F, Chopin C, Huart J J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.  Chest . 1993;  104 882-888
    PubMedGoogle Scholar
  • 29 Haire W D. Antithrombin III in hematopoietic stem cell transplantation.  Semin Thromb Hemost . 1997;  23 591-601
    PubMedGoogle Scholar
  • 30 Balk R, Emerson T, Fourrier F. Therapeutic use of antithrombin concentrate in sepsis.  Semin Thromb Hemost . 1998;  24 183-194
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Bucur S Z, Levy J H, Despotis G J, Spiess B D, Hillyer C D. Uses of antithrombin III concentrate in congenital and acquired deficiency states.  Transfusion . 1998;  38 481-498
    CrossrefPubMedGoogle Scholar
  • 32 Eisele B, Lamy M, Thijs L G. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.  Intensive Care Med . 1998;  24 663-672
    CrossrefPubMedGoogle Scholar
  • 33 Kanbak M. The treatment of heparin resistance with antithrombin III in cardiac surgery.  Can J Anaesth . 1999;  46 581-585
    PubMedGoogle Scholar
  • 34 Nakabayashi M, Asami M, Nakatani A. Efficacy of antithrombin replacement therapy in severe early-onset preeclampsia.  Semin Thromb Hemost . 1999;  25 463-466
    PubMedGoogle Scholar
  • 35 Vinazzer H. Hereditary and acquired antithrombin deficiency.  Semin Thromb Hemost . 1999;  25 257-263
    PubMedGoogle Scholar
  • 36 Williams M R, D'Ambra A B, Beck J R. A randomized trial of antithrombin concentrate for treatment of heparin resistance.  Ann Thorac Surg . 2000;  70 873-877
    CrossrefPubMedGoogle Scholar
  • 37 Houdebine L M. The production of pharmaceutical proteins from the milk of transgenic animals.  Reprod Nutr Dev . 1995;  35 609-617
    PubMedGoogle Scholar
  • 38 Echelard Y. Recombinant protein production in transgenic animals.  Curr Opin Biotechol . 1996;  7 536-540
    PubMedGoogle Scholar
  • 39 Meade H M, Echelard Y, Ziomek C A. Expression of recombinant proteins in the milk of transgenic animals. In: Fernandez JM, Hoeffler JP, eds. Gene Expression Systems: Using Nature for the Art of Expression, San Diego, CA: Academic Press; 1999: 399-427
    Google Scholar
  • 40 Clark A J. The mammary gland as a bioreactor: expression, processing, and production of recombinant proteins.  J Mammary Gland Biol Neopl . 1998;  3 337-350
    PubMedGoogle Scholar
  • 41 Ebert K M, DiTullio P, Barry C A. Induction of human tissue plasminogen activator in the mammary gland of transgenic goats.  Biotechnology . 1994;  12 699-702
    PubMedGoogle Scholar
  • 42 Edmunds T, Van Patten M S, Pollock J. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin.  Blood . 1998;  91 4561-4571
    PubMedGoogle Scholar
  • 43 Pollock D P, Kutzko J P, Birck-Wilson E. Transgenic milk as a method for the production of recombinant antibodies.  J Immunol Methods . 1999;  231 147-157
    CrossrefPubMedGoogle Scholar
  • 44 Roberts B, DiTullio P, Vitale J, Hehir K, Gordon K. Cloning of the goat beta-casein-encoding gene and expression in transgenic mice.  Gene . 1992;  121 255-262
    CrossrefPubMedGoogle Scholar
  • 45 Zettlmeissl G, Conradt H S, Nimtz M, Haigwood N, Paques E P. Influence of glycosylation on the functional properties of human therapeutic plasma proteins.  GBF Monogr Ser . 1991;  15 259-275
    PubMedGoogle Scholar
  • 46 Olson S T, Frances-Chmura A, Swanson R, Bjork I, Zettlmeissl G. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity.  Arch Biochem Biophys . 1997;  341 212-221
    CrossrefPubMedGoogle Scholar
  • 47 Garone L, Edmunds T, Hanson E. Antithrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155.  Biochemistry . 1996;  35 8881-8889
    CrossrefPubMedGoogle Scholar
  • 48 Minnema M C, Chang A C, Jansen P M. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli Blood .  2000;  95 1117-1123
    PubMedGoogle Scholar
  • 49 Taylor Jr B F, Emerson Jr E T, Jordan R, Chang A K, Blick K E. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons.  Circ Shock . 1988;  26 227-235
    PubMedGoogle Scholar
  • 50 Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells.  Biochem Biophys Res Commun . 1989;  163 1404-1411
    CrossrefPubMedGoogle Scholar
  • 51 Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells.  Thromb Res . 1990;  59 895-904
    CrossrefPubMedGoogle Scholar
  • 52 Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effects of antithrombin III (AT III) and Trp49-modified AT III on plasma level of 6-keto-PGF1 alpha in rats.  Thromb Res . 1995;  80 201-208
    CrossrefPubMedGoogle Scholar
  • 53 Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III.  Am J Physiol . 1996;  270 L921-L930
    PubMedGoogle Scholar
  • 54 Ostrovsky L, Woodman R C, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion.  Circulation . 1997;  96 2302-2310
    PubMedGoogle Scholar
  • 55 Fourrier F, Jourdain M, Tournoys A. Effects of a combined antithrombin III and protein C supplementation in porcine acute endotoxic shock.  Shock . 1998;  10 364-370
    PubMedGoogle Scholar
  • 56 Inthorn D, Hoffmann J N, Hartl W H, Muhlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis.  Shock . 1998;  10 90-96
    PubMedGoogle Scholar
  • 57 Dickneite G, Leithauser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock.  Arterioscler Thromb Vasc Biol . 1999;  19 1566-1572
    PubMedGoogle Scholar
  • 58 Hoffmann J N, Vollmar B, Inthorn D, Schildberg F W, Menger M D. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway.  Am J Physiol . 2000;  279 C98-C107
    PubMedGoogle Scholar
  • 59 Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications.  Semin Thromb Hemost . 1998;  24 27-32
    PubMedGoogle Scholar
  • 60 Dickneite G. Antithrombin III in animal models of sepsis and organ failure.  Semin Thromb Hemost . 1998;  24 61-69
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Neviere R, Tournoys A, Mordon S. Antithrombin III reduces mesenteric venule leukocyte adhesion and small intestine injury in endotoxemic rats.  Shock . 2001;  15 220-225
    PubMedGoogle Scholar
  • 62 Bachmann F, McKenna R, Cole E R, Najafi H. The hemostatic mechanism after open heart surgery: I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation.  J Thorac Cardiovasc Surg . 1975;  70 76-85
    PubMedGoogle Scholar
  • 63 Colman R W. Surface mediated defense reactions. The plasma contact activation system.  J Clin Invest . 1984;  73 1249-1253
    CrossrefPubMedGoogle Scholar
  • 64 Kluft C, Dooijewaard G, Emeis J J. Role of the contact system in fibrinolysis.  Semin Thromb Hemost . 1987;  13 50-68
    PubMedGoogle Scholar
  • 65 Woodman R C, Harker L A. Bleeding complications associated with cardiopulmonary bypass.  Blood . 1990;  76 1680-1697
    PubMedGoogle Scholar
  • 66 Furie B, Furie B C. Molecular and cellular biology of blood coagulation.  N Engl J Med . 1992;  326 800-806
    CrossrefPubMedGoogle Scholar
  • 67 Davie E W, Ratnoff O D. Waterfall sequence for intrinsic blood clotting.  Science . 1964;  145 1310
    CrossrefPubMedGoogle Scholar
  • 68 Vasalli J D, Sappino A P, Belin D. The plasminogen activator/plasmin system.  J Clin Invest . 1991;  88 1067-1072
    PubMedGoogle Scholar
  • 69 Ogston D, Ogston C M, Ratnoff O D, Forbes C D. Studies on a complex mechanism for the activation of plasminogen by kaolin and chloroform: the participation of Hageman factor and additional cofactors.  J Clin Invest . 1969;  48 1786-1801
    CrossrefPubMedGoogle Scholar
  • 70 Levin E G, Marzec U, Anderson J, Harker L A. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells.  J Clin Invest . 1984;  74 1988-1995
    CrossrefPubMedGoogle Scholar
  • 71 Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator.  Biochem Biophys Acta . 1982;  704 461-469
    PubMedGoogle Scholar
  • 72 Bick R L. The clinical significance of fibrinogen degradation products.  Semin Thromb Hemost . 1982;  8 302-330
    PubMedGoogle Scholar
  • 73 Slaughter T F. The coagulation system and cardiac surgery. In: Estafanous FG, Barash PG, Reves JG, eds. Cardiac Anesthesia: Principles and Clinical Practice, Vol 24 1994: 621-633
    Google Scholar
  • 74 Senning A. Plasma-heparin concentration in extracorporeal circulation.  Acta Chir Scand . 1959;  117 55-59
    PubMedGoogle Scholar
  • 75 Akl B F, Vargas G M, Neal J, Robillard J, Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.  J Thorac Cardiovasc Surg . 1980;  79 97-102
    PubMedGoogle Scholar
  • 76 Culliford A T, Gitel S N, Starr N. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass.  Ann Surg . 1981;  193 105-111
    PubMedGoogle Scholar
  • 77 Esposito R A, Culliford A T, Colvin S B. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.  J Thorac Cardiovasc Surg . 1983;  85 174-185
    PubMedGoogle Scholar
  • 78 Gravlee G P, Haddon W S, Rothberger H K. Heparin dosing and monitoring for cardiopulmonary bypass.  J Thorac Cardiovasc Surg . 1990;  99 518-527
    PubMedGoogle Scholar
  • 79 Horkay F, Martin P, Rajah S M, Walker D R. Response to heparinization in adults and children undergoing cardiac operations.  Ann Thorac Surg . 1992;  53 822-826
    CrossrefPubMedGoogle Scholar
  • 80 Hattersley P G. Activated coagulation time of whole blood.  JAMA . 1967;  196 436-440
    PubMedGoogle Scholar
  • 81 Bull B S, Korpeman R A, Heise W M, Briggs B D. Heparin therapy during extracorporeal circulation. I. Problems in existing heparin protocols.  J Thorac Cardiovasc Surg . 1975;  69 674-684
    CrossrefPubMedGoogle Scholar
  • 82 Bull B S, Huse W M, Brauer F S, Korpeman R A. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage.  J Thorac Cardiovasc Surg . 1975;  69 685-689
    CrossrefPubMedGoogle Scholar
  • 83 Babka R, Colby C, El-Etr A, Pifarre R. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery.  J Thorac Cardiovasc Surg . 1977;  73 780-782
    PubMedGoogle Scholar
  • 84 Horrow J C. Heparin reversal of protamine toxicity: Have we come full circle?.  J Cardiothorac Anesth . 1990;  4 539-542
    CrossrefPubMedGoogle Scholar
  • 85 Pifarre R, Babka R, Sullivan H J. Management of postop heparin rebound following cardiopulmonary bypass.  J Thorac Cardiovasc Surg . 1981;  81 378-381
    PubMedGoogle Scholar
  • 86 Verska J J. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis.  Ann Thorac Surg . 1977;  24 170-173
    PubMedGoogle Scholar
  • 87 Hill J D, Dontigny L, de Leval M. A simple method of heparin management during prolonged extracorporeal circulation.  Ann Thorac Surg . 1974;  17 129-134
    PubMedGoogle Scholar
  • 88 Metz S, Keats A S. Low activated clotting time does not increase postoperative bleeding.  Ann Thorac Surg . 1990;  49 440-444
    PubMedGoogle Scholar
  • 89 Brister S J, Ofosu F A, Buchanan M R. Thrombin generation during cardiac surgery: Is heparin the ideal anticoagulant?.  Thromb Haemost . 1993;  70 259-262
    PubMedGoogle Scholar
  • 90 Slaughter T F, LeBleu T H, Douglas Jr M J. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers.  Anesthesiology . 1994;  80 520-526
    CrossrefPubMedGoogle Scholar
  • 91 Boisclair M D, Lane D A, Philippou H. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass.  Blood . 1993;  82 3350-3357
    PubMedGoogle Scholar
  • 92 Smith R C, Leung J M, Mangano D T, SPI Research Group. Postoperative myocardial ischemia in patients undergoing coronary bypass graft surgery.  Anesthesiology . 1991;  74 464-473
    PubMedGoogle Scholar
  • 93 Ponari O, Corsi M, Manotti C. Predictive value of in vitro and in vivo studies for correct individual heparinization in cardiac surgery.  J Thorac Pathol Cardiovasc Surg . 1979;  78 87-94
    PubMedGoogle Scholar
  • 94 Miller W M, Binford J M, Hessel E A. Results of a survey of the professional activities of 811 cardiopulmonary perfusionists.  J Thorac Cardiovasc Surg . 1982;  83 385-389
    PubMedGoogle Scholar
  • 95 Soloway H B, Christiansen T W. Heparin anticoagulation during cardiac surgery in an AT-III deficient patient.  Am J Clin Pathol . 1980;  73 723-725
    PubMedGoogle Scholar
  • 96 Chung F, David T E, Watt J. Excessive requirement for heparin during cardiac surgery.  Can Anaesth Soc J . 1981;  28 280-282
    PubMedGoogle Scholar
  • 97 Hanowell S T, Kim Y D, Rattan V, MacNamara T E. Increased heparin requirement with hypereosinophilic syndrome.  Anesthesiology . 1981;  55 450
    PubMedGoogle Scholar
  • 98 Mabry C D, Read R C, Thompson B W, Williams G D, White H J. Identification of heparin resistance during cardiac and vascular surgery.  Arch Surg . 1979;  114 128-135
    PubMedGoogle Scholar
  • 99 Staples M H, Dunton R F, Karlson K J, Leonardi H K, Berger R L. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping.  Ann Thorac Surg . 1994;  57 1211-1216
    PubMedGoogle Scholar
  • 100 Dietrich W, Spannagl, Schramm W. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass.  J Thorac Cardiovasc Surg . 1991;  102 505-514
    PubMedGoogle Scholar
  • 101 Cloyd G M, D'Ambra M N, Akins C W. Diminished anticoagulant response to heparin in patients undergoing coronary bypass grafting.  J Thorac Cardiovasc Surg . 1987;  94 535-538
    PubMedGoogle Scholar
  • 102 Marciniak E, Gockerman J P. Heparin-induced decrease in circulating antithrombin-III.  Lancet . 1977;  2 581-584
    PubMedGoogle Scholar
  • 103 Addonizio V P, Fisher C A, Kappa J R, Ellison N. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK 36374).  Surgery . 1987;  102 796-807
    PubMedGoogle Scholar
  • 104 Kappa R, Fisher C, Berkowitz H D, Cottrell E D, Addonizio V P. Heparin induced platelet activation in sixteen surgical patients: diagnosis and management.  J Vasc Surg . 1987;  5 101-109
    PubMedGoogle Scholar
  • 105 Cornad J, LeCompte T, Horellon M H, Cazenave B, Sanama M. AT III in patients treated with subcutaneous or intravenous heparin.  Thromb Res . 1981;  22 507-511
    CrossrefPubMedGoogle Scholar
  • 106 Sabbagh A H, Chung G KT, Shuttleworth P, Applegate B J, Gabriel W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass.  Ann Thorac Surg . 1984;  37 466-468
    PubMedGoogle Scholar
  • 107 Barnette R E, Shupak R C, Pontius J, Rao A K. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass.  Anesth Analg . 1988;  67 57-60
    PubMedGoogle Scholar
  • 108 Dietrich W, Schroll A, Barankay A, Richter J A. Effect of antithrombin III substitution on heparin response during extracorporeal circulation.  Anesthesiology . 1985;  63 3A Abstract 
    PubMedGoogle Scholar
  • 109 Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass correlation with subclinical plasma coagulation.  Ann Thorac Surg . 1994;  58 799-804
    PubMedGoogle Scholar
  • 110 Zaidan J R, Johnson S, Byrnes R, Monroe S, Guffin A V. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery.  Anesth Analg . 1986;  65 377-380
    PubMedGoogle Scholar
  • 111 Levy J H, Montes F, Szlam F, Hillyer C D. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy.  Anesth Analg . 2000;  90 1076-1079
    CrossrefPubMedGoogle Scholar
  • 112 Despotis G J, Levine V, Joist J H, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.  Anesth Analg . 1997;  85 498-506
    PubMedGoogle Scholar
  • 113 Rihal C S, Flather M, Hirsh J, Yusuf S. Advances in antithrombotic drug therapy for coronary artery disease.  Eur Heart J . 1995;  16S 10-21
    PubMedGoogle Scholar
  • 114 Yue R H, Gertler M M, Starr T, Koutrouby R. Alteration of plasma antithrombin III levels in ischemic heart disease.  Thromb Haemost . 1976;  35 598-606
    PubMedGoogle Scholar
  • 115 Losito R, Gattiker H, Bilodeau G, Longpre B. Natural coagulation inhibitors: an assessment in patients.  Ann NY Acad Sci . 1981;  370 714-719
    PubMedGoogle Scholar
  • 116 Vaziri N D, Kennedy S C, Kennedy D, Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris.  Am J Med . 1994;  96 651-657
    PubMedGoogle Scholar
  • 117 Granger C B, Miller J M, Bovill E G. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.  Circulation . 1995;  91 1929-1935
    PubMedGoogle Scholar
  • 118 Lidon R M, Theroux P, Robitaille D. Antithrombin III plasma activity during and after prolonged use of heparin in unstable angina.  Thromb Res . 1993;  72 23-32
    CrossrefPubMedGoogle Scholar
  • 119 Biasucci L M, Liuzzo G, Caligiuri G. Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina.  Circulation . 1996;  93 2121-2127
    PubMedGoogle Scholar
  • 120 Merlini P A, Ardissino D, Bauer K A. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes.  Arterioscler Thromb Vasc Biol . 1997;  17 1325-1330
    PubMedGoogle Scholar
  • 121 Grip L, Blombäck M, Egberg N. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.  Eur Heart J . 1997;  18 443-449
    PubMedGoogle Scholar
  • 122 Lu W, Mant T, Levy J H, Bailey J M. Pharmacokinetics of recombinant transgenic antithrombin in volunteers.  Anesth Analg . 2000;  90 531-534
    PubMedGoogle Scholar
  • 123 Levy J H, Despotis G J, Olson P J, Weisinger A, Szlam F. Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery.  Blood . 1997;  90(Suppl I) 298A Abstract 
    PubMedGoogle Scholar